Paul Appermont

Last updated

Paul Appermont (born 1946 in Bilzen) is a Belgian businessman. Together with Joos Horsten, he laid the foundation of Xi'an Janssen Pharmaceutical. [1] Appermont is a member of the board of EuropaBio.

Contents

Education

Appermont graduated with a PhD in Law at the Katholieke Universiteit Leuven (Leuven, Belgium) [2] and in International Relations at the Graduate Institute of International Studies (IUHEI) (Geneva, Switzerland).

Career

Paul Appermont started his career at Janssen Pharmaceutica as company lawyer. In 1979 he and Joos Horsten were sent to Xi'an, the capital of Shaanxi province, in the People's Republic of China by Dr. Paul Janssen to prepare for the establishment of a pharmaceutical company. In 1986 he started working for Biogen in Switzerland as a Vice President of trade and licensing. In 1896 he joined Jean-Louis Gentilini in the development of Medicard. He now works as a consultant for Innogenetics and the biotech industry. [3]

Notes

Related Research Articles

<span class="mw-page-title-main">Johnson & Johnson</span> American multinational pharmaceutical and consumer goods corporation

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

<span class="mw-page-title-main">Paul Janssen</span> Belgian scientist, founder of Janssen Pharmaceutica

Paul Adriaan Jan, Baron Janssen was a Belgian physician. He was the founder of Janssen Pharmaceutica, a pharmaceutical company with over 20,000 employees which is now a subsidiary of Johnson & Johnson.

<span class="mw-page-title-main">Janssen Pharmaceuticals</span> Belgian pharmaceutical company

Janssen Pharmaceuticals is a pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen.

Janssen may refer to:

<span class="mw-page-title-main">Janssen Vaccines</span> Biotechnology subsidiary of Johnson & Johnson

Janssen Vaccines, formerly Crucell, is a biotechnology company specializing in vaccines and biopharmaceutical technologies. It was formed when Johnson & Johnson acquired the Dutch biotech company Crucell based in Leiden and placed it in their pharmaceutical division.

Cilag AG is a Swiss pharmaceutical company. Cilag is a subsidiary of American pharmaceutical giant Johnson & Johnson. The company's global marketing activities are operated by Janssen-Cilag, a merger with another Johnson & Johnson subsidiary, Janssen Pharmaceuticals.

Bernhard Joos, was the son of Dr. Bernhard Joos and Olga Sturzenegger.

Paul, Baron Stoffels is a Belgian MD, who studied medicine at the University of Hasselt and the University of Antwerp (UA). In addition he studied Infectious Diseases and Tropical Medicine at the Prince Leopold Institute of Tropical Medicine in Antwerp, Belgium. He is Chief Scientific Officier, Worldwide Chairman of Janssen pharmaceuticals and he is a member of the Johnson & Johnson Executive Committee.

<span class="mw-page-title-main">Rudi Pauwels</span>

Rudi Pauwels is a Belgian pharmacologist and biotech entrepreneur.

Didier R.G.G. de Chaffoy de Courcelles is a Belgian scientist and businessman. He was senior vice president of Drug Discovery Europe, and Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica, until 2008 when he left the company.

Dr. Jan Constant Janssen was a Belgian physician and businessman. He was the third child of Adriaan Victor Janssen (1854–1942) and Anna Catharina Eelen (1855–1929). He went to high school in Hoogstraten and studied medicine at the Catholic University of Leuven and the University of Ghent. On 16 April 1925, he married Margriet Fleerackers, together they had four children. Their oldest son, Paul Janssen, would become one of the most successful scientists in pharmaceutics.

Bob Stouthuysen Belgian businessman (born 1929)

Baron Robert "Bob" Stouthuysen is a Belgian businessman. He is honorary president of the Vlaams Economisch Verbond and of Janssen Pharmaceutica. He lives in Turnhout in the Campine region of Flanders.

Erik Tambuyzer is a Belgian bio-engineer and businessman. He is Chairman of the Board of the Flemish Center for Medical Innovation (CMI).

Staf Van Reet is a Belgian scientist and businessman. Currently he is Managing Director of the biotech company Viziphar Biosciences BVBA, and member of the Board of Directors of Janssen Pharmaceutica and the VIB. He was succeeded as Chairman of FlandersBio by Johan Cardoen.

Joos Horsten (1942–2008) was a Belgian businessman. He founded Xian Janssen Pharmaceutical, the Sino-Belgian joint venture of Janssen Pharmaceutica, a Flemish pharmaceutical company in Belgium.

Jan A. J. Schuurkes is a Dutch biologist and gastrointestinal researcher.

Els Vanheusden is a Belgian physician, businesswoman and from 2004 until 31 May 2008, General Manager of FlandersBio, the cluster of the Flemish biotech industry. She was succeeded by Ann Van Gysel on 1 June 2008.

Ortho-McNeil-Janssen Pharmaceuticals, Inc is a healthcare company of Johnson & Johnson composed of two divisions:

Patrick Schöffski

Patrick Schöffski is a German medical doctor specializing in internal medicine, hematology and medical oncology.

Pharmaceutical industry in Switzerland Overview of the pharmaceutical industry in Switzerland

The pharmaceutical industry in Switzerland directly and indirectly employs about 135,000 people. It contributes to 5.7% of the gross domestic product of Switzerland and contributes to 30% of the country's exports. In 2017 about 30% of Swiss exports were chemical products. In the same year Switzerland was the second largest exporter of packaged medicine in the world, with about 11% of the global total, worth $36.5 billion.

References